Allergan Inc., maker of the wrinkle smoother Botox, won U.S. approval to sell the first prescription medicine to enhance dull or thinning eyelashes.
The Food and Drug Administration cleared the solution, called Latisse, after a unanimous recommendation from its outside advisers, Allergan said this morning.
Latisse contains the same main ingredient as Allergans Lumigan, on the market for glaucoma since 2001.
The Irvine, Calif.-based company is targeting Latisse at the $3.7 billion-a-year global market for mascara.
Latisse may bring in $80 million annually by 2012, and the opportunity could be much larger longer term, said Gary Nachman, a Leerink Swann & Co. analyst in New York, in a Dec. 8 note to clients.
-- Bloomberg News
Email
Facebook
Google
Twitter
Favorites
More
Advertisement